盐酸安罗替尼或甲磺酸阿帕替尼治疗晚期实体恶性肿瘤的效果及对患者凝血功能的影响  

The efficacy of anlotinib hydrochloride or apatinibmesylate in the treatment of advanced solid malignant tumors and its impact on patient coagulation function

作　　者：刘安龙 郭翔 刘辉 LIU Anong;GUO Xiang;LIU Hui(Department of Hematology and Oncology,the Nuclear Industry 417 Hospital,Xi'an,Shaanxi,710600,China)

机构地区：[1]核工业四一七医院血液肿瘤科,陕西西安710600

出　　处：《当代医学》2024年第6期135-139,共5页Contemporary Medicine

摘　　要：目的探究盐酸安罗替尼或甲磺酸阿帕替尼治疗晚期实体恶性肿瘤的效果及对患者凝血功能的影响。方法回顾性分析2019年5月至2022年5月核工业四一七医院收治的78例晚期实体恶性肿瘤患者的临床资料,根据治疗方案不同分为对照组与观察组,每组39例。对照组行常规姑息治疗,观察组给予盐酸安罗替尼或甲磺酸阿帕替尼治疗。比较两组临床疗效及治疗前后凝血功能、血常规指标水平,并统计观察组不良反应发生情况及不良反应级别。结果观察组客观缓解率、疾病控制率为28.21%、76.92%,均高于对照组的0.00%、21.74%,差异有统计学意义(P<0.05)。治疗后,观察组活化部分凝血活酶时间(APTT)长于对照组,D二聚体(D-D)、血小板计数(PLT)水平均低于对照组,差异有统计学意义(P<0.05)。观察组高血压、乏力、口腔黏膜炎、消化道反应、出血、尿蛋白发生率分别为20.51%、17.95%、12.82%、30.77%、5.13%、12.82%,不良反应分级均为1~2级,仅1例出血达到3级。结论盐酸安罗替尼或甲磺酸阿帕替尼治疗晚期实体恶性肿瘤患者,可提升治疗效果,改善凝血功能,不良反应相对轻微,但需关注出血情况。Objective To investigate the efficacy of anlotinib hydrochloride or apatinib methanesulfonate in the treatment of advanced solid ma-lignant tumors and its impact on patient coagulation function.Methods The clinical data of 78 patients with advanced solid malignant tumors admit-ted to the Nuclear Industry 417 Hospital from May 2019 to may 2022 were retrospectively analyzed,they were divided into the control group and the observation group according to different treatment plans,with 39 cases in each group.The control group received routine palliative treatment,while the observation group received treatment with anlotinib hydrochloride or apatinib mesylate.The clinical efficacy,the levels of coagulation function and blood routine indicators before and after treatment were compared between the two groups,and record the incidence and level of adverse reac-tions in the observation group.Results The objective remission rate and disease control rate in the observation group were 28.21%and 76.92%,which were higher than 0.00%and 21.74%in the control group,and the differences were statistically significant(P<0.05).After treatment,the acti-vated partial thromboplastin time(APTT)in the observation group was longer than that in the control group,and the levels of D-dimer(D-D)and platelet count(PLT)were lower than those in the control group,with the differences were statistically significant(P<0.05).The incidence rates of hypertension,fatigue,oral mucositis,gastrointestinal reactions,bleeding,and urinary protein in the observation group of patients were 20.51%,17.95%,12.82%,30.77%,5.13%,and 12.82%,respectively,the adverse reaction grades were all 1-2,with only 1 case of bleeding reaching level 3.Conclusion The application of amlotinib hydrochloride or apatinib mesylate in the treatment of advanced solid malignant tumors can improve treat-ment efficacy,improve coagulation function,and have relatively mild adverse reactions,but attention should be paid to bleeding.

关 键 词：晚期实体恶性肿瘤 盐酸安罗替尼 凝血功能 

分 类 号：R733[医药卫生—肿瘤]